Do senolytics like dasatinib and quercetin actually work in humans?

The best human evidence on senolytics so far comes from a 60-woman trial that missed its primary target. Mayo Clinic researchers randomized postmenopausal women to intermittent dasatinib plus quercetin or a control group for 20 weeks. The trial used 100 mg of dasatinib on two days and 1,000 mg of quercetin a day on three days, repeated every 28 days (see [1]). The primary endpoint, the bone breakdown marker CTx, did not differ from control at 20 weeks. A bone formation marker, P1NP, rose 16 percent at two and four weeks, then faded.

The interesting part is who responded. Women in the top third for T cell p16, a proxy for senescent cell burden, saw P1NP rise 34 percent and CTx fall 11 percent at two weeks, and wrist bone density climb 2.7 percent versus control by week 20 (see [1]). That was an exploratory analysis with roughly ten women per arm, so it is a hypothesis, not a result. It does fit a pattern I watched for years in biotech: a drug that clears a target only helps people who carry enough of that target.

The rest of the human record is thin. The first senolytic study in people, 14 patients with idiopathic pulmonary fibrosis, reported better walking distance and gait speed, but it was open label with no control group, and lung function did not change (see [2]). In a 2025 overview, the senior author of the bone trial counted only nine published senolytic trials, just two with a control group, against dozens still registered (see [3]). He argued the next trials should enroll people selected for a high senescent cell burden.

So the honest answer is that we don't have strong evidence yet that senolytics slow aging in people, and there is no validated consumer test that says who would respond. Store-bought quercetin is not the trial regimen, and dasatinib needs a prescription, which puts it firmly in the worth-discussing-with-a-physician category. Meanwhile the interventions with decades of human data, fitness, strength, sleep and blood pressure, are what to measure over time, and they are the features to look for in our comparison of longevity apps.

This is general information, not medical advice. Talk to a qualified clinician about your own situation.